“Natural history” of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

Élias, Dominique; Pietrantonio, Daniela Di; Boulet, Thomas; Honoré, Charles; Bonnet, Stéphane; Goèré, Diane; Kohneh-Shahri, N.; Raynard, Bruno

doi:10.1016/j.ejso.2008.02.009

Cited by 21 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is essential that surgery resects all the tumor implants exceeding 1 mm, as the drugs penetration in the tissue and in the tumor deposits is small, less than 1 to 2 mm [29,30]. HIPEC must be performed immediately after surgery to avoid peritoneal adhesions in which cancer cells may be trapped and could constitute a tumor sanctuary [31][32][33][34]. In fact, the exact effect of HIPEC alone in this package is currently unknown in human beings.…”

Section: Evidence For Crs and Hipec For Pm From Colorectal Cancermentioning

confidence: 99%

Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

Bhatt

Goèré

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Occurring either synchronously or metachronously to the primary tumor, peritoneal metastases (PM) are diagnosed in 8 to 20 % of the patients with colorectal cancer (CRC). Prognosis of these patients appears to be worse than those with other sites of metastases. While systemic therapy has shown significant prolongation of survival in patients with stage IV colorectal cancer, the outcomes in the subset of patients with PM has been much inferior. Over the last 2 decades, cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) have been effective in substantially prolonging survival in patients with colorectal PM and have the potential to cure certain patients as well. This article reviews the current evidence for CRS and HIPEC to treat colorectal PM as well as future research going on in this form of locoregional treatment.

show abstract

Section: Evidence For Crs and Hipec For Pm From Colorectal Cancermentioning

confidence: 99%

Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

Bhatt

Goèré

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…The complications observed after surgical cytoreduction followed by HIPEC in our study are compatible with those reported in previous studies. [8,14,20] The morbidity rate after surgical cytoreduction followed by HIPEC for peritoneal carcinomatosis was extremely high (∼40%). [20] Cytoreductive surgery and HIPEC have a steep learning curve, requiring 140 procedures to acquire expertise.…”

Section: Discussionmentioning

confidence: 99%

“…[8,14,20] The morbidity rate after surgical cytoreduction followed by HIPEC for peritoneal carcinomatosis was extremely high (∼40%). [20] Cytoreductive surgery and HIPEC have a steep learning curve, requiring 140 procedures to acquire expertise. [21] Thus far, we have performed HIPEC in >300 patients with peritoneal carcinomatosis in our institute.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…However, large retrospective studies showed 5-year survival rates of up to 27%, with CCR [36,37] and lymph node metastases at the time of CRS and HIPEC [38] being major prognostic factors. It was recently reported by van Oudheusden et al [39] that in a small patient group, patients with peritoneal carcinomatosis of signet cell CRC who underwent CRS and HIPEC had a poor outcome, with a median survival of 14 months.…”

Section: Peritoneal Metastasesmentioning

confidence: 99%

Oligometastatic Disease in the Peritoneal Space with Gastrointestinal Cancer

Rau¹,

Brandl²,

Pascher³

et al. 2017

Visc Med

View full text Add to dashboard Cite

Objectives: Treatment options for patients with gastrointestinal cancer and oligometastastic disease remain the domain of the medical oncologist. However, in selected cases, attempts to remove or destroy the tumor burden seem appropriate. Background Data: During the last decade, the treatment of localized and isolated tumor nodules, such as lung, liver or peritoneal metastasis, has changed. Previously, these patients with metastatic disease only received palliative chemotherapy. Combined treatment approaches and new techniques demonstrate that additional surgery to destroy or remove the metastases seem to be of major benefit to patients. Methods: The recently published important literature regarding peritoneal metastases and oligometastases in gastrointestinal cancer was analyzed. Results: The most important factor in the treatment of peritoneal metastases and in cytoreductive surgery is patient selection. Resection of peritoneal metastases should be considered. Hyperthermic intraperitoneal chemotherapy is feasible. However, further results of randomized trials are necessary. Several randomized trials are on the way and will be available in 1-2 years. Systemic chemotherapy alone as an adequate management plan for all sites of metastatic disease is not compatible with a high standard of care. Formulating an optimal plan combining re-operative surgery with regional plus systemic chemotherapy is a necessary task of the multidisciplinary team. Conclusions: In oligometastastic disease of gastrointestinal cancer origin, the selection process is the most important factor for survival. Further studies are needed to determine optimal treatment options.

show abstract

“Natural history” of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

Cited by 21 publications

References 12 publications

Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis

Oligometastatic Disease in the Peritoneal Space with Gastrointestinal Cancer

Contact Info

Product

Resources

About